Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

Infectious Disease·MeSH: Non-alcoholic Fatty Liver Disease
1 drug in development·1 company·2 clinical trials

Drug Pipeline by Phase

Phase 3(1)
DrugCompany
Pegozafermin89bio, Inc. (ETNB)

Frequently asked questions

How many drugs are in development for Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis?

BioSniper tracks 1 drug in development for Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis across 1 company.

How many clinical trials target Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis?

There are 2 clinical trials targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis tracked by BioSniper.

Deep-dive into Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis — Drugs in Development & Clinical Trials | BioSniper